II. Guidelines for Prevention, Diagnosis and Treatment of Ventilator-Associated Pneumonia (VAP) in the Trauma

Ventilator-associated pneumonia (VAP*) is the most common nosocomial infection encountered in the ICU setting. Injured patients are particularly prone to VAP due in part to injuries such as direct chest trauma with pulmonary contusion and inability to control oropharyngeal secretions associated with traumatic brain injury. Post-injury immunosuppression is a recognized complicating factor of severe injury. Furthermore, common therapies used in caring for injured patients, such as blood transfusion, total parenteral nutrition and repeated trips to the operating room add to this immunocompromised state. The Centers for Disease Control (CDC), through the National Nosocomial Infections Surveillance System (NNIS), report that the median rate of VAP per 1000 ventilator days for patients in trauma ICU’s (11.4) was higher than any other individual type of surgical ICU (general surgery, cardiac surgery, neurosurgical, etc.). This rate was more than double that seen in medical (3.7) or coronary care (4.0) ICU’s. 1 The mortality and morbidity attributable to VAP is difficult to ascertain. In a matched cohort study looking at a mixed population, the relative risk of death attributable to pneumonia was 32%. 2 This increase was only significant in medical ICU patients where the relative risk of death attributable to pneumonia was 65%, suggesting an episode of VAP tips the balance for the medically frail. It is likely that surgical patients, by virtue of either being selected by surviving operative intervention (or their injuries) have adequate reserve such that an episode of VAP is less likely to be fatal. However, the additional length of stay (4–6 days) and associated costs, 3 coupled with the detrimental effects of antimicrobial use on ICU ecology, calls for aggressive prevention strategies and a practical, evidence-based approach to managing VAP in critically ill trauma patients. Despite its common occurrence, there is still no agreed upon “gold standard” for the diagnosis of VAP and contro

[1]  J. Minei,et al.  Inflammation and the Host Response to Injury, a Large-Scale Collaborative Project: patient-oriented research core--standard operating procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of ventilator-associated pneumonia (VAP) in the trauma patient. , 2006, The Journal of trauma.

[2]  D. Cook,et al.  Evidence-Based Clinical Practice Guideline for the Prevention of Ventilator-Associated Pneumonia , 2004, Annals of Internal Medicine.

[3]  Jeanne E. Zack,et al.  An educational intervention to reduce ventilator-associated pneumonia in an integrated health system: a comparison of effects. , 2004, Chest.

[4]  Marin H Kollef,et al.  A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. , 2004, Chest.

[5]  D. Spain,et al.  The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures. , 2004, The Journal of trauma.

[6]  The Crash trial management group,et al.  Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia , 2004, Intensive Care Medicine.

[7]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[8]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[9]  Alexander J. Davit,et al.  A prospective assessment of diagnostic efficacy of blind protective bronchial brushings compared to bronchoscope-assisted lavage, bronchoscope-directed brushings, and blind endotracheal aspirates in ventilator-associated pneumonia. , 2003, The Journal of trauma.

[10]  J. Meredith,et al.  Optimal threshold for diagnosis of ventilator-associated pneumonia using bronchoalveolar lavage. , 2003, The Journal of trauma.

[11]  Jordi Rello,et al.  Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. , 2002, Chest.

[12]  Victoria J. Fraser,et al.  Experience with a clinical guideline for the treatment of ventilator-associated pneumonia , 2001, Critical care medicine.

[13]  M. Bonten,et al.  Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. , 2001, American journal of respiratory and critical care medicine.

[14]  V L Yu,et al.  Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.

[15]  T. Similowski,et al.  Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.

[16]  Miquel Ferrer,et al.  Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial , 1999, The Lancet.

[17]  D. Cook,et al.  The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. , 1999, American journal of respiratory and critical care medicine.

[18]  M. Kollef,et al.  The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. , 1998, Chest.

[19]  N B Hampson,et al.  The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria. , 1997, Chest.

[20]  T. Fabian,et al.  Using bronchoalveolar lavage to distinguish nosocomial pneumonia from systemic inflammatory response syndrome: a prospective analysis. , 1994, The Journal of trauma.

[21]  Incidence of Ventilator-associated Pneumonia , 2022 .